Company intelligence / Profile preview

Centre for Oncology and Immunology

Hong Kong, Hong Kong

Ownership: Private
Employees: ~100
Development stage: Preclinical

Overview

COI has developed next-generation organoid-based cell models, contributed to immunotherapy/checkpoint inhibitor strategies now used clinically, and created a diagnostic test for Lynch Syndrome. Their current work focuses on identifying new druggable targets in hard-to-treat cancers using advanced biotechnology platforms.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodySmall moleculeCell therapy
Industry: Academic Hospital/University/Research

Partnerships

HKU/HKUMed (as part of InnoHK government initiative)

Beyond the preview

Go deeper on Centre for Oncology and Immunology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centre for Oncology and Immunology.

Explore the full profile